Adult Vaccines: Fact vs. Fiction
Addressing patient misconceptions and uncertainty remains important to help get routine adult vaccinations back on schedule.
Experimental mRNA Vaccine Plus Keytruda Delays Melanoma Recurrence
A new study shows that a personalized messenger RNA (mRNA) cancer vaccine plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk of recurrence or death in people with high-risk advanced melanoma.
The Spread of Misinformation and Its Effects on Vaccines
The effects of exposure to misinformation about vaccines has been exacerbated by the COVID-19 pandemic. And, misinformation continues to flourish with damaging consequences.
Personalized Cancer Vaccine Development
Research into targeted, effective vaccines for cancer remains ongoing.
CDC Adds COVID-19 Vaccine to Its Routine Immunization Schedule
The Centers for Disease Control and Prevention updated its schedule of recommended immunizations to include COVID-19 shots and boosters for children, adolescents and adults.
Regen BioPharma Files Patent for mRNA Cancer Vaccine
Regen BioPharma has filed a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented mRNA cancer immunotherapeutic vaccine.
First Malaria Vaccine Prequalified by WHO
The World Health Organization has prequalified the first malaria vaccine, RTS,S/AS01 (also known as Mosquirix), manufactured by GSK, bringing it closer to reaching millions more children at risk of malaria.
Study Finds Universal Influenza B Vaccine Induces Broad and Lasting Protection
A study by researchers at Georgia State University’s Institute of Biomedical Sciences has found a new universal flu vaccine has been found to protect against influenza B viruses that offer broad defenses against different strains and improve immune protection.
Researchers Develop a New mRNA Vaccine to Treat Cancer
U.S. researchers have developed a new mRNA vaccine against cancer that delivers the drug directly to the lymphatic system and simulates a strong immune response.
Study Finds Pfizer’s RSV Vaccine Effective in Preventing Illness in Older Adults
Results of a recent study shows Pfizer’s experimental vaccine for respiratory syncytial virus is nearly 86 percent effective in preventing severe illness in older adults.
